Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12930221 | 1.00 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL12930036 | 1.00 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL12799380 | 1.00 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL7603707 | 1.00 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL12899874 | 1.00 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL13626821 | 0.81 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL12899659 | 0.81 | CDA (0.41) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL11997793 | 0.81 | — | — | |
| SCHEMBL12979133 | 0.81 | CDA (0.41) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL5579411 | 0.81 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313735-A1 | Improved Fluorination Process | SANDOZ AG (CH) | 2017-11-02 | — | — | US | disclosed |
| US-9309275-B2 | 3′-deoxy nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-12 | — | — | US | disclosed |
| US-9192621-B2 | Esters and malonates of SATE prodrugs | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140248241-A1 | 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-09-04 | — | — | US | disclosed |
| US-20140086873-A1 | Esters and Malonates of SATE Prodrugs | IDENIX PHARMACEUTICALS LLC | 2014-03-27 | — | — | US | disclosed |
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | CDA 421/4885PDE4D 2578/4885PDE3A 2230/4885 |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | G6PD, GALE, UGGT1 | CDA 520/4885PDE4D 2886/4885PDE3A 2842/4885 |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | CDA 1085/4885PDE4D 3817/4885PDE3A 2687/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | CDA 238/4885PDE4D 2157/4885PDE3A 1247/4885 |
| US-20140248241-A1 | 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, NUDT1, SLC28A1 | CDA 78/4885PDE4D 1661/4885PDE3A 875/4885 |
| US-20170313735-A1 | Improved Fluorination Process | SF3B5, PFAS, AFF1 | CDA 2813/4885PDE4D 3818/4885PDE3A 2995/4885 |
| US-20140086873-A1 | Esters and Malonates of SATE Prodrugs | ME1, SLC10A1, UGT1A1 | CDA 1446/4885PDE4D 4654/4885PDE3A 4593/4885 |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | CDA 1085/4885PDE4D 3817/4885PDE3A 2687/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | CDA 421/4885PDE4D 2578/4885PDE3A 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.